Loading...
Vertex Pharmaceuticals Incorporated
0QZU.L•LSE
Healthcare
Medical - Pharmaceuticals
£457.48
£-1.43(-0.31%)
Vertex Pharmaceuticals Incorporated (0QZU.L) Financial Performance & Statements
Review Vertex Pharmaceuticals Incorporated’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
11.66%
↑ 11.66%
Operating Income Growth
-105.41%
↓ 105.41%
Net Income Growth
-114.80%
↓ 114.80%
Operating Cash Flow Growth
-113.93%
↓ 113.93%
Operating Margin
-6.69%
↓ 6.69%
Gross Margin
86.03%
↑ 86.03%
Net Profit Margin
-8.91%
↓ 8.91%
ROE
-6.25%
↓ 6.25%
ROIC
-3.89%
↓ 3.89%
Vertex Pharmaceuticals Incorporated (0QZU.L) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Vertex Pharmaceuticals Incorporated stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.91B | $2.77B | $2.63B | $2.69B |
| Cost of Revenue | $423.40M | $392.60M | $371.90M | $342.60M |
| Gross Profit | $2.49B | $2.38B | $2.26B | $2.34B |
| Gross Profit Ratio | $0.85 | $0.86 | $0.86 | $0.87 |
| R&D Expenses | $998.70M | $875.90M | $5.42B | $865.90M |
| SG&A Expenses | $377.60M | $371.80M | $372.20M | $342.70M |
| Operating Expenses | $1.38B | $1.26B | $5.79B | $1.21B |
| Total Costs & Expenses | $1.89B | $1.66B | $6.16B | $1.55B |
| Interest Income | $128.20M | $132.20M | $156.50M | $181.20M |
| Interest Expense | $2.80M | $7.50M | $9.90M | $10.40M |
| Depreciation & Amortization | $46.50M | $53.20M | $54.00M | $53.50M |
| EBITDA | $1.18B | $1.28B | -$3.33B | $1.34B |
| EBITDA Ratio | $0.41 | $0.46 | -$1.26 | $0.50 |
| Operating Income | $1.03B | $1.12B | -$3.53B | $1.14B |
| Operating Income Ratio | $0.35 | $0.40 | -$1.34 | $0.42 |
| Other Income/Expenses (Net) | $110.50M | $107.80M | $123.50M | $139.60M |
| Income Before Tax | $1.14B | $1.22B | -$3.39B | $1.28B |
| Income Before Tax Ratio | $0.39 | $0.44 | -$1.29 | $0.48 |
| Income Tax Expense | $223.50M | $178.70M | $202.40M | $179.50M |
| Net Income | $913.00M | $1.05B | -$3.59B | $1.10B |
| Net Income Ratio | $0.31 | $0.38 | -$1.36 | $0.41 |
| EPS | $3.55 | $4.05 | -$13.92 | $4.26 |
| Diluted EPS | $3.50 | $4.01 | -$13.92 | $4.21 |
| Weighted Avg Shares Outstanding | $257.50M | $258.00M | $258.10M | $258.20M |
| Weighted Avg Shares Outstanding (Diluted) | $260.50M | $261.00M | $258.10M | $261.10M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan